Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 14/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30273140 | 0.84 | PARP1 (0.61) | PARP1KIF11KDM4EALDH1A1 | |
| SCHEMBL7027018 | 0.77 | PARP1 (0.48) | PARP1KIF11KDM4EALDH1A1 | |
| SCHEMBL30577720 | 0.76 | PARP1 (0.74) | PARP1KDM4EPARP15TNKS2 | |
| SCHEMBL13688018 | 0.76 | PARP1 (0.69) | PARP1KIF11KDM4EALDH1A1MEN1 | |
| SCHEMBL25093568 | 0.73 | PARP1 (0.46) | PARP1KDM4EALDH1A1 | |
| SCHEMBL30577714 | 0.73 | PARP1 (0.46) | PARP1KDM4EALDH1A1 | |
| SCHEMBL25738485 | 0.72 | PARP1 (0.38) | PARP1KIF11KDM4EALDH1A1LMNA | |
| SCHEMBL29203560 | 0.72 | PARP1 (0.68) | PARP1KIF11KDM4EALDH1A1KMT2A | |
| SCHEMBL10134731 | 0.72 | FLT3 (0.44) | PARP1 | |
| SCHEMBL25093566 | 0.71 | PARP1 (0.51) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368169-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI), INC. (CN) | 2024-11-07 | — | — | US | disclosed |
| EP-4392425-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF | Impact Therapeutics (Shanghai), Inc. (CN) | 2024-07-03 | — | — | EP | disclosed |
| WO-2023025307-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2023-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368169-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF | PARP1, PARP2, PARP11 | PARP1 1/4885KIF11 3787/4885KDM4E 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.